# A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Study · id `cardio:ct-nct05196035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05196035](<https://clinicaltrials.gov/study/NCT05196035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05196035

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 219 participants.

## Technical summary

Registry record NCT05196035. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-28 (actual); primary completion 2027-04-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 219 participants (planned count; ClinicalTrials.gov record NCT05196035, source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)
- Started: 2022-03-28 (actual) (ClinicalTrials.gov record NCT05196035, source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)
- Primary completion: 2027-04-10 (anticipated) (ClinicalTrials.gov record NCT05196035, source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)
- Completion: 2027-05-10 (anticipated) (ClinicalTrials.gov record NCT05196035, source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Lithuania; Malaysia; Mexico; Netherlands; Poland; Portugal; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05196035, source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05196035-2026-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- Acronym: FIONA
- Condition: Chronic Kidney Disease
- Condition: Proteinuria
- Intervention (Drug): Finerenone (Kerendia, BAY94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: b6a11c52014e16bc9452b1d4d8324ce2339de313572082cede82a94028b674d5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
